Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8778717 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL8663677 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL19604963 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL6378123 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL1679629 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL11390770 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL17320713 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL20145736 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL8892986 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 | |
| SCHEMBL11390785 | 1.00 | FAAH (0.59) | FAAHCA2TSHRTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300143-A | Water soluble dye, sulfone, and amide or cyclic amine | XEROX CORPORATION (US) | 1994-04-05 | — | — | US | claimed |
| US-20230288610-A1 | WAVELENGTH SELECTIVE ABSORPTION FILTER AND DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11753399-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-3820290-A1 | FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS | Université de Lausanne (CH) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020011750-A1 | FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS | Université de Lausanne (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-9975888-B2 | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-05-07 | — | — | US | disclosed |
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013125733-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE USING THE SAME AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2013-08-29 | — | — | WO | disclosed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | disclosed |
| WO-2005123387-A2 | ELECTRO-ACTIVE ADHESIVE SYSTEMS | ENTEGRIS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050274455-A1 | Electro-active adhesive systems | ENTEGRIS, INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | ISHIBASHI MICHIO (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6878745-B2 | Selective preventives/remedies for progressive lesions after organ damage | Ishibashi, Michio (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0602914-B1 | Ink compositions for ink jet printing | XEROX CORP (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0602914-A1 | Ink compositions for ink jet printing | XEROX CORPORATION (US) | 1994-06-22 | — | — | EP | disclosed |
| US-5300143-A | Water soluble dye, sulfone, and amide or cyclic amine | XEROX CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | FAAH 2777/4885CA2 749/4885TSHR 3380/4885 |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | FAAH 786/4885CA2 528/4885TSHR 4135/4885 |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | CD68, MSR1, CCL2 | FAAH 1761/4885CA2 534/4885TSHR 3555/4885 |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | FAAH 4244/4885CA2 3833/4885TSHR 4329/4885 |
| US-11753399-B2 | Therapeutic compounds | NPC1, CCR5, FURIN | FAAH 4419/4885CA2 2227/4885TSHR 4855/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | FAAH 2023/4885CA2 2333/4885TSHR 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.